Global Non-invasive Prenatal Testing Market Growth Rate 2024, Forecast To 2033
17 Jan, 2024
The non-invasive prenatal testing market has experienced rapid growth, elevating from $4.73 billion in 2023 to $5.44 billion in 2024, reflecting a remarkable 15.1% CAGR. This growth is linked to improved accuracy, reduced risk, increased maternal age, growing awareness, and adherence to clinical guidelines. Future projections estimate a market size of $9.43 billion in 2028, fueled by expanding test offerings, wider accessibility, rising maternal age, fetal anomaly detection, and the integration of telemedicine. Major trends encompass expanded test panels, increased adoption of NIPT, technological advancements, and non-invasive fetal aneuploidy diagnosis.
Global Non-invasive Prenatal Testing Market Key Driver
The high incidence rate of Down syndrome propels the non-invasive prenatal testing (NIPT) market. With an older maternal age leading to concerns about fetal safety, NIPT screening tests are non-invasive, carrying no risk of miscarriage and detecting over 99% of Down syndrome cases. In the USA, 1 in every 700 babies is born with Down syndrome, and 80% of these cases occur in older mothers. The increased risk among older women contributes to the growth of the non-invasive prenatal testing market.
Get A Free Sample Of The Global Non-invasive Prenatal Testing Market ReportGlobal Non-invasive Prenatal Testing Market Segments
The non-invasive prenatal testing market covered in this report is segmented –
1) By Type: Consumables, Instruments
2) By Application: Trisomy, Microdeletion, Genetics, Rh factor
3) By End User: Hospital, Diagnostic Labs
Subsegment: NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, Others(Centrifuges, UV Systems, Incubators, Microscopes), Assay Kits &Reagents, Disposables
By Geography: The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the non-invasive prenatal testing market in 2023. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Non-invasive Prenatal Testing Industry Players
F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Beijing Genomics Institute, Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc.
Get The Full Global Non-invasive Prenatal Testing Market Report
Non-invasive Prenatal Testing Market Overview
Non-invasive prenatal testing is a test in which blood from the mother is drawn and tested for possible abnormalities in the patient. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy.
Non-invasive Prenatal Testing Global Market Report 2023 provides data on the global non-invasive prenatal testing market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The non-invasive prenatal testing market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.